[Intrathecal Baclofen Therapy for Spastic Paralysis]

Area of Science:

• Neurology
• Neurosurgery
• Pharmacology

Context:

• Spastic paralysis significantly impacts patient quality of life and mobility.
• Current medical therapies for severe spasticity have limitations in efficacy and tolerability.
• Intrathecal baclofen therapy (ITB) offers a targeted drug delivery system for managing spasticity.

Purpose:

• To describe the principles, indications, and outcomes of intrathecal baclofen therapy (ITB).
• To outline the surgical procedure and potential complications associated with ITB pump implantation.
• To discuss the long-term management requirements and future prospects of ITB therapy.

Summary:

• ITB involves implanting a pump for direct intrathecal baclofen administration, enabling lower effective doses compared to oral routes.
• Indications include severe spastic paraparesis unresponsive to conventional treatments or complicated by side effects.
• Pump implantation is considered if a trial of intrathecal baclofen shows improvement in spasticity.

Impact:

• ITB provides a viable treatment option for severe spasticity, potentially improving functional outcomes and reducing medication-related adverse events.
• Understanding postoperative care, including medication refills and device maintenance, is crucial for successful long-term management.
• Further popularization of ITB therapy in regions like Japan is anticipated to benefit more patients with debilitating spasticity.